Hangzhou Adamerck Pharmaceuticals

Adlai Nortye is a global clinical-stage biotechnology company specializing in the development of innovative oncology therapies with a focus on immuno-oncology. Founded in 2004 and formerly known as Hangzhou Adamerck Pharmaceuticals, the company operates R&D and clinical centers in both Hangzhou, China, and North Brunswick, New Jersey. Its lead asset, buparlisib (AN2025), is a pan-PI3K inhibitor currently in a global Phase 3 trial for recurrent or metastatic head and neck squamous cell carcinoma. The pipeline also includes AN0025, a small molecule EP4 antagonist, and AN4005, an oral PD-L1 inhibitor, alongside several early-stage biologics targeting TNFR2 and other immune checkpoints. Adlai Nortye leverages strategic collaborations with major pharmaceutical companies, including Novartis and Eisai, to accelerate the development of its diverse portfolio. The company successfully listed on the NASDAQ in 2023 to support its mission of transforming cold tumors into hot tumors.